AIMS To compare ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) mortality between Sweden and the UK, adjusting for background population rates of expected death, case mix, and treatments. METHODS AND RESULTS National data were collected from hospitals in Sweden [n = 73 hospitals, 180 368 patients, Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART)] and the UK [n = 247, 662 529 patients, Myocardial Ischaemia National Audit Project (MINAP)] between 2003 and 2013. There were lower rates of revascularization [STEMI (43.8% vs. 74.9%); NSTEMI (27.5% vs. 43.6%)] and pharmacotherapies at time of hospital discharge including [aspirin (82.9% vs. 90.2%) and (79.9% vs. 88.0%), β-blockers (73.4% vs. 86.4%) and (65.3% vs. 85.1%)] in the UK compared with Sweden, respectively. Standardized net probability of death (NPD) between admission and 1 month was higher in the UK for STEMI [8.0 (95% confidence interval 7.4-8.5) vs. 6.7 (6.5-6.9)] and NSTEMI [6.8 (6.4-7.2) vs. 4.9 (4.7-5.0)]. Between 6 months and 1 year and more than 1 year, NPD remained higher in the UK for NSTEMI [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] and [21.4 (20.0-22.8) vs. 18.3 (17.6-19.0)], but was similar for STEMI [0.7 (0.4-1.0) vs. 0.9 (0.7-1.0)] and [8.4 (6.7-10.1) vs. 8.3 (7.5-9.1)]. CONCLUSION Short-term mortality following STEMI and NSTEMI was higher in the UK compared with Sweden. Mid- and longer-term mortality remained higher in the UK for NSTEMI but was similar for STEMI. Differences in mortality may be due to differential use of guideline-indicated treatments.

中文翻译：

---

842 897 名欧洲人急性心肌梗死后的死亡率统计。


目的 比较瑞典和英国之间 ST 段抬高型心肌梗死 (STEMI) 和非 STEMI (NSTEMI) 死亡率，并根据预期死亡率、病例组合和治疗的背景人口率进行调整。方法和结果 全国数据收集自瑞典的医院 [n = 73 家医院，180 368 名患者，瑞典根据推荐疗法评估的心脏病循证护理网络系统 (SWEDEHEART)] 和英国 [ n = 247, 662 529 名患者，心肌缺血国家审计项目 (MINAP)] 2003 年至 2013 年间。血运重建率较低 [STEMI（43.8% vs. 74.9%）； NSTEMI（27.5% vs. 43.6%）]和出院时的药物治疗，包括[阿司匹林（82.9% vs. 90.2%）和（79.9% vs. 88.0%）、β-受体阻滞剂（73.4% vs. 86.4%）和(65.3% vs. 85.1%)]英国与瑞典分别。在英国，STEMI [8.0（95% 置信区间 7.4-8.5）与 6.7（6.5-6.9）] 和 NSTEMI [6.8（6.4-7.2）与4.9（4.7-5.0）]。在 6 个月至 1 年以及 1 年以上期间，英国 NSTEMI 的 NPD 仍然较高 [2.9 (2.5-3.3) vs. 2.3 (2.2-2.5)] 和 [21.4 (20.0-22.8) vs. 18.3 (17.6- 19.0)]，但 STEMI 相似[0.7 (0.4-1.0) 与 0.9 (0.7-1.0)] 和 [8.4 (6.7-10.1) 与 8.3 (7.5-9.1)]。结论 与瑞典相比，英​​国 STEMI 和 NSTEMI 后的短期死亡率较高。英国 NSTEMI 的中长期死亡率仍然较高，但 STEMI 的死亡率相似。死亡率的差异可能是由于指南指示的治疗方法的不同使用造成的。